Covid-19 vaccine: India will increase biotech production with another 200 million doses of covacin

Covid-19 vaccine: India will increase biotech production with another 200 million doses of covacin

Photo Credit: Bharat Biotech

New Delhi: India Biotech said on Thursday that it would produce another 200 million doses of COVID-19 vaccine at its subsidiary in Ankleshwar, Gujarat. With this the total annual production of the company will reach one billion doses. The Hyderabad-based company said it would use its wholly owned subsidiary Shiron Behring Vaccines Production Plant in Ankleshwar to produce another 200 million doses of cocaine.

India Biotech said in a statement, “The company plans to produce 200 million doses of covaxin per year at GMP plants. These are underway.” Read more: Corona Vaccine: For the second day in a row in Mumbai, people did not take Kovacin supplement

The company said it has already deployed several production lines for the vaccine at its Hyderabad and Bangalore campuses. India Biotech’s 100 per cent subsidiary Shiron Behring Vaccines is one of the world’s leading manufacturers of rabies vaccines.

(This is a monitored and auto-generated story from a syndicated news feed, most likely not modified or edited by recent staff)

Avatar

About soumitra Mondal

Hi dear friends, I hope you are all well. My name is Soumitra mondal and I am a blogger. Friends, in this website I have told you about the latest technology updates. This website is an informatics website only.

View all posts by soumitra Mondal →

Leave a Reply

Your email address will not be published. Required fields are marked *